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1. Introduction 
Glycosylation is one of the most complex post-translation modifications, commonly found 
in many cell surface and secreted eukaryotic proteins. 1-2% of the human transcriptome 
encodes proteins that link to glycosylation. Many protein-based biotherapeutics approved 
or in clinical trials are glycoproteins. The oligosaccharides covalently attached to therapeutic 
glycoproteins pose biological benefits as well as manufacturing challenges. The present 
chapter reviews the structure and function of glycosylation, glycoform patterns observed for 
the biotherapeutic proteins produced by various host systems, and analytic methods for the 
characterization of glycoforms. Recent advances in utilizing glycosylation as a strategy to 
improve biotherapeutics properties are also discussed. 
2. Glycosylation as a major post-translational modification 
Glycosylation has been studied intensively for the past two decades as the most common 
covalent protein modification in eukaryotic cells (Varki 2009). Sophisticated oligosaccharide 
analysis has revealed a remarkable complexity and diversity of this post-translational 
modification. About 1-2% of the human transcriptome (about 250-500 glycogenes) has been 
predicted to encode proteins that are involved in glycosylation processing (Campbell and 
Yarema 2005). Majority of proteins synthesized in the endoplasmic reticulum (ER) such as cell 
surface and extracellular eukaryotic proteins are glycoproteins. It has been estimated that more 
than 50% of proteins in human are glycosylated (Apweiler et al. 1999; Wong 2005).  
Glycoproteins can be classified into four groups: N-linked, O-linked, glycosaminoglycans, 
and glycosylphosphatidylinositol-anchored proteins (Table 1). This chapter focuses only on 
N- and O-linked glycosylation. N-linked glycosylation is through the side chain amide 
nitrogen of a specific asparagine residue, while O-linked glycosylation is through the 
oxygen atom in the side chain of serine or threonine residues. The N-linked modification 
takes place in both ER and Golgi, while the O-linked glycosylation in higher eukaryotes 
occurs exclusively in the Golgi.  
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-------------------------------------------------------------------------------------------------------------------------- 
        Type                              Consensus site             Sugar structures          Synthesis Location 
-------------------------------------------------------------------------------------------------------------------------- 
(1) N-linked       N-X-T/S          High mannose         ER, Golgi 
                                                                           Complex-type 
                                                                                 Hybrid-type 
-------------------------------------------------------------------------------------------------------------------------- 
(2) O-linked       Ser/Thr                    Mucin-type                  Golgi 
                                                                                        O-linked fucose 
                                                                                        O-linked glucose 
                                                                                        O-linked GlcNAc 
-------------------------------------------------------------------------------------------------------------------------- 
(3) Glycosaminoglycans      Asn/Ser/Thr           Glycosaminoglycans   ER, Golgi 
-------------------------------------------------------------------------------------------------------------------------- 
(4) Glycosylphosphatidylinositol                            glycosylphosphatidylinositol  
                                    phosphatidylinositol /                                              ER, Golgi 
                                    phosphoethanolamine  
                                    to protein carboxyl terminus  
-------------------------------------------------------------------------------------------------------------------------- 
Table 1. Glycoproteins Categories 
Comparing to other major molecular constituents of cells such as nucleic acids and proteins, 
the biological importance of glycans or carbohydrates in the post-translational modification 
has been much later appreciated (Varki 2009). There is no single theory explaining why cells 
go through such complex and highly conserved biosynthetic machineries. Though not all 
answers are known, it is now clear that glycosylation plays many key biological functions 
such as protein folding, stability, intracellular and inter-cellular trafficking, cell-cell and cell-
matrix interaction (Varki 1993; Varki 2009).  
It is therefore not surprising that congenital disorders with serious medical consequences 
have been identified linked to the defects in a number of genes in glycosylation pathway 
(Freeze 2006). Over 40 such disorders have been reported to be associated with glycogene 
mutations, and many more to be discovered. In addition, glycosylation profiles of specific 
proteins change as certain diseases progress, such as cancers and rheumatoid arthritis, and 
have been regarded as disease and diagnostic markers.  
This chapter focuses on the biological structures and physiological roles of glycosylation 
modification in the context of biotherapeutics. Glycosylation differences in proteins 
produced by various host systems, and the potential impacts on biotherapeutics safety and 
side effects, are described. Various analytical characterization methods for glycoforms are 
also described. Lastly, several therapeutic examples with glycoengineering application are 
illustrated and discussed. 
2.1 Structure and biosynthesis 
N-linked glycosylation occurs in the sequon of Asn-X-Ser/Thr where X can be any amino 
acid except proline and aspartic acid (Helenius and Aebi 2004; Kornfeld and Kornfeld 1985). 
Glycosylation at Asn-Ala-Cys has also been reported (Stenflo and Fernlund 1982). 
Glycosylation efficiency of these Threonine, Serine, and Cysteine containing sequon is very 
different with an order of Thr>Ser>Cys (Bause and Legler 1981). N-linked oligosaccharides 
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are added to proteins en bloc in the lumen of ER as pre-synthesized core units of 14 
saccharides (Glc3Man9GlcNAc2) in virtually all eukaryotes. This core glycan is the product of 
a biosynthesis pathway in which monosaccharides are added to a lipid carrier (dolichol-
pryophosphate) on both sides of the ER membrane by monosaccharyltransferases in the 
membrane. The sugar moiety is translocated from cytosolic side to the luminal side of the 
ER by an ATP-independent bidirectional flippase (Hirschberg and Snider 1987). The 
oligosaccharyltransferase then scans the emerging polypeptide from translocon complex for 
glycosylation sequon and adds the core glycan unit to the side chain nitrogen of the Asn 
residue by N-glycosidic bond. The oligosaccharides are added to the sequon when it is only 
12-14 residues into the ER lumen, as the active site of the oligosaccharytransferase is no 
further than 5nm away from the exit of the protein translocon (Nilsson and von Heijne 
1993). 
After the core glycan is added to the growing nascent polypeptide chain, the oligosaccharide 
portion is modified by a series of glycosidases and glycosyl transferases. Various complex, 
hybrid, and high mannose types of N-linked oligosaccharides are generated. Glucosidase I 
and II located in the ER remove all three glucose residues from the core unit to produce a 
Man9GlcNAc2 high mannose structure. Hybrid and complex oligosaccharides can be 
produced from high mannose structures, from which -mannosidases in the ER and the 
Golgi remove 4-6 mannoses. Then Golgi-bound glycosyl transferases add GlcNAc as well as 
galactoses and sialic acids to produce complex types of oligosaccharides. These 
modifications reflect a spectrum of functions related to glycoprotein folding, quality control, 
sorting, degradation, and secretion. 
O-linked glycosylation normally takes place in the Golgi, most commonly initiated with a 
transfer of N-acetylgalactosamine (GalNAc) to a serine or threonine residue by an N-acetyl 
galactosaminyltransferase (Van den Steen et al. 1998). After the addition of the first GalNAc, 
a number of glycosyltransferases and enzymes in the Golgi can elongate the core structure 
and modify it with sialylation, fucosylation, sulphatation, methylation or acetylation(Van 
den Steen et al. 1998). O-linked glycosylation site is not readily predicted, any serine or 
threonine residue is a potential site and O-linked sugars are frequently clustered in short 
regions of peptide chain that contain repeating units of Serine, Threonine, and Proline. 
There are various types of O-linked sugars, including mucin-type O-glycans commonly 
found in many secreted and membrane-bound glycoproteins in higher eukaryotes, O-linked 
fucose and O-linked glucose found in the epidermal growth factor domains of different 
proteins, and O-linked GlcNAc on cytosolic and nuclear proteins. Yeast’s O-linked 
oligomannose glycans take place in the ER utilizing dolichol-phosphate-mannose instead of 
a sugar nucleotide, which is similar to N-linked glycosylation occurred co-translationally 
(van den Steen et al, 1998). 
2.2 Physiological function and roles 
Protein folding and conformation stabilization function of N-linked glycans were first 
suggested by the early studies with tunicamycin, a glycosylation inhibitor (Olden et al. 
1982). The sequential processing by glucosidases, mannosidases, and glycotranferases, of the 
core unit of 14 saccharides, provides recognition tags for lectins mediated folding pathway 
(Helenius and Aebi 2004). The content of oligosaccharides can regulate protein half-life. 
Large amount of sialic acids can increase plasma half-life while exposure of galactose and 
mannose can decrease half-life (Walsh and Jefferis 2006). N-glycans also play a critical role 
in intracellular trafficking with a well understood example of mannose-6-phosphate of 
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lysosomal enzymes (Kornfeld and Mellman 1989). For Antibodies, oligosaccharide moieties 
covalently attached at the highly conserved Asn297 at the CH2 domain of the Fc 
(crystallizable fragment) region, is critical to the activation of downstream effector 
mechanisms (Jefferis 2009; Natsume et al. 2009). Completely aglycosylated or 
deglycosylated IgGs do not bind effector receptors such as FcRI, FcRII, and FcRIII (Leader 
et al. 1991; Leatherbarrow et al. 1985; Walker et al. 1989). Sialylated IgGs have a lower 
affinity to FcRIIIA than non-sialylated IgGs, consequently a lower antibody-dependent 
cellular cytotoxicity (ADCC) activity (Kaneko et al. 2006; Scallon et al. 2007). Removal of 
terminal galactose residues from Fc glycans reduces complement-dependent cytotoxicity 
(CDC) activity (Boyd et al. 1995; Kumpel et al. 1995). Absence of a core -1, 6 linked fucose 
from Fc glycans improves in vitro ADCC activity (Niwa et al. 2004; Shields et al. 2002).  
O-linked glycosylation plays a role in maintaining secondary, tertiary, and quaternary 
structures of fully folded proteins. The examples are mucins and related molecules, in which 
peptide regions with O-linked sugar attachments assume a “bottle brush”-like structure 
(Carraway and Hull 1991; Gowda and Davidson 1994). Like N-glycans, O-glycans can 
modulate aggregation, maintain protein stability, confer protease and heat resistance. An 
example of O-linked sugars hindering protease cleavage is the modification at the hinge 
regions of IgA1 and IgD (Field et al. 1994; Van den Steen et al. 1998). O-linked glycosylation 
is important for the expression and processing of particular proteins such as glycophorin A 
(Remaley et al. 1991) and IGF-II (Daughaday et al. 1993). They are also crucial for some 
glycoprotein-protein interaction, such as the interaction between P-selectin glycoprotein 
ligand-1 (PSGL-1) and P Selectin. Some O-linked oligosaccharides of PSGL-1 have a terminal 
sialyl-Lewis-x structure, which is important for its P-selectin receptor function (Hooper et al. 
1996). 
3. Glycoproteins as biotherapeutics 
More than one-third of approved biotherapeutics and many in clinical trials are 
glycoproteins (Walsh and Jefferis 2006). The presence and nature of the oligosaccharides 
clearly affect these protein drugs’ folding, stability, trafficking, immunogenicity as well as 
their primary activities.  
3.1 Antibodies and Fc-fusion proteins 
Therapeutic recombinant antibodies and fusion proteins of Fc region of immunoglobulin G1 
(IgG1) represent a major class of biotherapeutics. An individual antibody molecule contains 
two light and two heavy polypeptide chains, forming two identical Fab (antigen-binding 
fragment) regions with a specific antigen-binding site, and a homodimeric IgG-Fc region. 
This Fc region is critical for phagocytosis, ADCC activity, CDC activity, and FcRn binding 
for recycling. As discussed above, the N-glycans attached to Asn297 in Fc region are critical 
to the activation of downstream effector mechanisms, while not affecting FcRn binding for 
catabolic half-life. 
Besides the presence of core glycans at the Fc regions, about 30% of polyclonal human IgG 
molecules contain N-linked oligosaccharides within the IgG-Fab region (Jefferis 2009). The 
N-linked sites can be at the variable regions of either heavy chains or light chains or both. 
The licensed antibody therapeutics cetuximab has an N-linked glycan at Asn88 of the heavy 
chain variable region, and an unoccupied N-linked motif at Asn41 of the light chain variable 
region (Qian et al. 2007). Fab oligosaccharide is heterogeneous complex diantenary and 
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hybrid oligosaccharides with sialic acids and galactoses, which are very different from the 
Fc oligosaccharides with predominantly fucosylated non-galactosylated diantennary 
oligosaccharides. The difference may be due to the inaccessibility of Fc N-glycan for further 
modification, as the N-glycans at the Fc regions are integral to the IgG structure and has a 
defined confirmation (Jefferies, 2009). Many Fc-fusion therapeutics proteins, such as 
TNFRII-Fc, CD2-Fc, and CTLA4-Fc, contain glycosylation modifications in the fusion 
portions, in addition to their Fc glycans. The contents of these glycosylations are very 
similar to those of Fab oligosaccharides.  
3.2 Non-immunoproteins 
Many non-immunoproteins such as growth factors, cytokines, hormones, and therapeutic 
enzymes, are glycoproteins. Growth factors such as erythropoietin (EPO) have three N-
linked and one O-linked sugar side chains. Removal of either two (Asn38 and Asn83) or all 
three sites results in poor product secretion (Egrie 1993). Cytokines such as interferon(IFN)-
 and IFN- are glycoproteins (Pestka et al. 1987). Although glycosylation is not essential for 
INFs protein efficacy or safety, lack of glycosylation decreases their biological activity and 
circulatory half-life. Oligosaccharide structures of follicle-stimulating hormone heterodimer 
play an important role in its biosynthesis, secretion, metabolic fate, and functional potency 
(Ulloa-Aguirre et al. 1999). The glycans at each subunit seem to exhibit distinct roles, with 
those in ǂ subunit critical for dimer assembly, signal transduction, and secretion, and those 
in ǃ subunit more crucial for circulation clearance. In addition, many therapeutics enzymes 
such as recombinant human glucocerebrosidase for Gaucher disease (Van Patten et al. 2007) 
are glycoproteins and N-glycosylation is important for its targeting and functional activities. 
3.3 Effects of glycosylation on therapeutic efficacy of glycoproteins 
In comparison to small-molecule drugs, therapeutic proteins display a number of favorable 
therapeutic properties, such as higher target specificity, good pharmacological potencies, 
and lower side effects, but they also possess intrinsic limitations like poor physicochemical 
and pharmacological properties. Glycosylation of therapeutic glycoproteins can improve 
therapeutic efficacy through its positive impact on protein pharmacodynamics (PD) and 
pharmacokinetics (PK).  
Pharmacodynamics refers to the potency of therapeutic proteins as enzymatic rates and 
receptor binding affinities. Pharmacokinetics exams the time dependency of drug action, 
which is influenced by drug absorption, distribution, excretion, initial response times and 
duration of effects. The parameters include circulatory half-life, volumes of distribution, 
clearance rates, and total bioavailability. Protein drugs’ PK/PD are typically affected by 
adverse local adsorption in subcutaneous administration due to variable protein 
hydropathy surface, and by rapid elimination from body in intravenous administration, via 
proteolytic, renal, hepatic, and receptor mediated clearance mechanisms (Mahmood and 
Green 2005; Tang et al. 2004). 
Glycosylation has multiple impacts on PK/PD properties of therapeutics glycoproteins. 
First, glycosylation can shield non-specific proteolytic degradation, as discussed above. 
Second, sialic acids at the terminus of glycan chains carry negative charge, which reduces 
renal clearance most likely due to repulsion from negatively charged polysaccharides on 
membranes in the glomerular filter (Chang et al. 1975; Venkatachalam and Rennke 1978). 
Third, size of glycans can increase protein molecular weight and hydrodynamic radius of 
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glycoprotein and therefore reduce glomerular filtration. Fourth, terminal sialic acids of 
glycan branches prevent the exposure of galactose, N-acetyl-glycosamine, or mannose that 
interacts with hepatic asialoglycoprotein receptor as well as other mammalian lectin-like 
receptors to be removed from circulation. 
4. Glycosylation in various cell production systems 
Glycosylation patterns of biotherapeutics are highly variable based on the production 
systems (Table 2) and their culture processes. Mammalian cells such as Chinese Hamster 
Ovary cells (CHO) and mouse myeloma cells (NS0, SP2/0) are the most commonly used 
systems. Alternative cell production systems are being developed and explored. 
 
-------------------------------------------------------------------------------------------------------------------------- 
  Host systems                  Similarity to human glycans                Abnormal sugars 
-------------------------------------------------------------------------------------------------------------------------- 
  CHO    High         trace amount of -Gal, NGNA 
 
  NS0/SP2/0   High         small amount of -Gal, NGNA 
 
  Yeast    Low         high mannose 
 
  Plant    Low         bisecting 1,2 xylose, 1,3 fucose 
 
  Transgenic animals  Low         high mannose and NGNA 
-------------------------------------------------------------------------------------------------------------------------- 
Table 2. Glycans comparison in various production systems   
The glycoforms of CHO-produced IgGs are close to human IgGs, but having very little 
glycoform with the third N-acetylglucosamine bisecting arm, which makes up about 10% of 
human IgG glycoforms, and also very low amount of terminal N-acetyl neuraminic acid is 
generated. The glycosylation in mouse-derived cells such as NS0 and SP2/0 shows even 
more difference from human glycoforms. They produce small amounts of glycoforms with 
additional -1,3-galactose (-Gal) and a different predominant sialic acid, N-Glycolyl 
neuraminic acid (NGNA). NGNA is reported to be immunogenic in human (Sheeley et al. 
1997), and in certain patient populations, -Gal is associated with IgE-mediated 
anaphylactic responses, with the best known example of cetuximab (Chung et al. 2008). 
Detection of both -Gal and NGNA in CHO-derived glycans is also reported, but only in 
trace amount (Hamilton and Gerngross 2007; van Bueren et al. 2011). 
Yeast, insect cells, plants, and transgenic animals, are the alternative systems to the current 
mammalian hosts. They are being actively explored for biotherapeutics production because 
of their lower manufacture cost. However, restricted abilities to generate human-like 
glycoforms are their major limitations, as different glycosylation machinery yields 
immunogenic recombinant glycoproteins. For instance, complex type N-glycans are very 
different in plants and mammals. Plant N-glycans contain a bisecting 1,2 xylose in place of 
 mannose core, an 1,3 fucose instead of an 1,6 fucose, and are highly heterogeneous 
(Gomord et al. 2005), and allergenic. Glycans from yeast (Hamilton et al. 2006) and insect 
(Shi and Jarvis 2007) have a high mannose content, resulting a quick clearance through 
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binding to macrophage mannose receptor in the liver. IgGs produced in the milk of 
transgenic goats contain 50% NGNA and a higher level of mannose (Edmunds et al. 1998). 
Tremendous efforts have focused on “humanization” of the glycosylation pathways in these 
alternative systems to improve product consistency and pharmacokinetics, while decreasing 
the potential immunogenicity for product antibody response.  
5. Analytic characterization of glycoforms 
Various glycosylation analysis approaches (Table 3)  have been developed and utilized for 
glycoform characterization. Glycans can be enzymatically or chemically released from 
glycoproteins, prior to electrophoretic, chromatographic or mass spectrometric analysis. 
Glycoproteins can also be treated with endoproteinases, followed by glycosylation analysis 
at the glycopeptides level. 
 
-------------------------------------------------------------------------------------------------------------------------- 
 Methods            Principles                    Major advantages and shortcoming 
-------------------------------------------------------------------------------------------------------------------------- 
(1) Electrophoresis 
 
 SDS-PAGE           Size       General equipment, cheap, fast 
                                                                              High-throughput possible, 
 IEF             Charge               Limited resolution 
 
(2) Chromatography (HPLC)       Polarity                High resolution 
                                                                                        Separation of major glycoforms 
                                                                                         Risk of hydrolysis 
 
(3) Mass spectrometry           Mass                        Detailed information, fast 
                                                                                       High resolution, precise   
                                                                                       Expensive equipment 
                                                                                        Trained personnel 
-------------------------------------------------------------------------------------------------------------------------- 
Table 3. Glyco-analytical methods  
5.1 Electrophoresis 
Sodium Docedyl sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and 
IsoElectrofocusing electrophoresis (IEF) are two methods that are routinely used for gross 
glycoprotein characterization. SDS-PAGE is for separation of mass variant due to the 2kDa 
mass addition of a single N-glycan. When treated with glycanase such as PNGase F and 
Endo-H, a migration shift can be detected. IEF is for separation of charge variants. The sialic 
acid content of glycans can increase negative charge of glycoproteins, while the PNGase F 
treatment generates a negatively charged aspartic acid instead of the neutral N-glycan 
linked asparagines.   
5.2 Liquid chromatography 
Normal phase high-performance liquid chromatography (NP-HPLC) is one of the most 
commonly used analytical methods to analyze oligosaccharides after enzymatic release and 
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fluorescent labeling. The glycans can be accurately quantified and detected in sub-picomolar 
levels (Guile et al. 1996). Different peaks in an NP-HPLC chromatogram can be isolated and 
submitted to off-line analysis by mass spectrometry or to sequential digestion with selective 
exoglycosidases (neuraminidase, ǂ-galactosidase, ǃ-galactosidase, ǃ-hexoaminidase, ǂ-
fucosidase, ǂ-mannosidase, ǃ-mannosidase) for further biochemical confirmation. NP-HPLC 
can also be used for routine IgGs glycan finger printing for IgGs expressed in different cell 
lines.  
5.3 Mass spectrometry 
Mass spectrometry is a fast and powerful method to differentiate and estimate the relative 
proportion of different glycoforms. Glycans and glycopeptides are traditionally ionized by 
fast atom bombardment and laser desorption. In the past two decades, softer ionization 
techniques such as Electrospray Ionization-Time-of-Flight (ESI-TOF) and Matrix-assisted 
laser desorption ionization (MALDI) provide a much higher sensitivity and precision. It 
allows measuring intact glycoproteins and investigating non-symmetry of N-linked 
biantennary oligosaccharides between two heavy chains on intact antibodies (Beck et al. 
2008). 
6. Glycoengineering to improve protein therapeutics 
It is obvious that selectively producing a certain type of glycoforms of biotherapeutics 
protein could be advantageous in terms of efficacy and safety. Residue screening with site-
directed mutagenesis is widely used to introduce or eliminate N-glycosylation sites (Zhong 
et al. 2009). Though there is no “one-size-for-all” principle and guideline, the process has 
been aided by knowledge of the known structure and function of the target protein so that 
the changes can retain in vitro biological activity, stability, and high sugar occupancy rate. 
Cell line engineering to knock-out and knock-in glycogenes is another approach to enrich 
desired glycoforms. It is also possible to use in vitro glycoenzymes to modify glycoform 
profiles. The following are a few specific examples. 
6.1 Half-life extension 
One well known glycoengineering application is altering pharmacokinetic property of 
therapeutic proteins. Introducing new N-linked glycosylation site into target proteins to 
increase sialic acid containing carbohydrates can increase in vivo activity due to a longer 
half-life. This technology has been successfully applied to produce a hyperglycosylated 
analogue of recombinant human erythropoietin (Elliott et al. 2003). This glycoengineered 
protein contains two additional N-linked carbohydrates, which result in a threefold increase 
in serum half-life and a less frequent dosing for anemic patients (Sinclair and Elliott 2005). 
Sialic acid containing carbohydrates are highly hydrophilic and therefore increase protein 
solubility by shielding hydrophobic residues. Similar approach has been applied to a 
number of therapeutic proteins, including human growth hormone (Flintegaard et al. 2010), 
follicle stimulating hormone(Perlman et al. 2003), Leptin and Mpl ligand (Elliott et al. 2003). 
In case of human growth hormone, the terminal half-life in rats for  the sialylated protein 
with three additional N-linked glycans was prolonged by 24-fold compared with that of 
wild type protein (Flintegaard et al. 2010). The correlation between half-life optimization 
and N-linked carbohydrate addition remain unclear. 
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6.2 Glycoengineered antibody for ADCC modulation 
N-glycans in the Fc-region of IgG1 play a critical role in ADCC activity. Absence of a core -
1, 6 linked fucose  improves binding to FcRIII and in vitro ADCC activity (Niwa et al. 2004; 
Shields et al. 2002). Addition of bisecting GlcNAc, which also results in the removal of core 
fucose, significantly enhances ADCC activity (Davies et al. 2001; Shinkawa et al. 2003; 
Umana et al. 1999). ADCC enhancement has also been shown for non-fucosylated IgG4 
(Niwa et al. 2005), for Fc fusion proteins (TNFRII-Fc) (Shoji-Hosaka et al. 2006), for single 
chain-Fc and bispecific antibodies (Natsume et al. 2006). Several glycoengineered antibodies 
such as anti-GD3 (BioWa), anti-CD20 (Glycart-Roche), and anti-IL5R (BioWa/Medimmune) 
are currently being investigated in clinical trials.  
Besides defucosylation, sialylation is also utilized for antibody and Fc engineering. 
Sialylated IgGs have been found to possess a lower ADCC activity than non-sialylated IgGs 
(Kaneko et al. 2006; Scallon et al. 2007). Overexpressing gal and sialic transferases in CHO 
results in sialylation increase of ≥ 90% of available glycan branches in Fc-fusion proteins 
(Weikert et al. 1999).  
6.3 Mannose for target delivery 
Engineered glycosylation has been employed for targeted delivery to disease affected 
tissues. One well established example is the treatment of lysosomal storage diseases. 
Recombinant human enzymes such as glucocerebrosidase can be digested with 
exoglycosidases to expose mannose or mannose-6-phosphate that can efficiently target the 
enzymes into the lysosomes of macrophages. The high mannose modified enzymes can also 
be produced by a glycosylation mutant such as Lec1 mutant (Van Patten et al. 2007), or by 
treatment of chemical inhibitors (Zhou et al. 2008). Targeting the protein drugs to the 
desired site by glycoengineering have significantly increased therapeutic efficacy of a 
number of replacement enzymes, including -glucosidase, -galatosidase, and -L-
iduronidase (Sola and Griebenow 2010). 
7. Conclusions and future directions 
Glycosylation modification offers both an opportunity and a challenge to biotherapeutics 
glycoproteins. Complexity and heterogeneity of oligosaccharides present a considerable 
challenge to the biopharmaceutical industry to manufacture biotherapeutics with a 
reproducible and consistent glycoform profile. Meanwhile, a better understanding of the 
structure and function of glycosylation modification to glycoproteins can better facilitate the 
development of next-generation of biotherapeutics with optimized glycoforms and 
therapeutic utilities. Further humanization of glycosylation machinery in non-mammalian 
expression systems may represent a trend in lowering the manufacture cost for 
biotherapeutics such as antibodies and Fc-fusion proteins. With a full development of 
glycoanalytical techniques, an improved knowledge on glycoprotein activity in vivo will 
certainly help design a safer and more efficacious biotherapeutics drugs.  
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